Separate Chinese lines for prostate cancer?

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2019,（2）
• 页码范围: 212
• 页数: 1页
• 语种: 英文

摘要

The recent report of Chinese patients treated with abiraterone is important.It debates whether previous reports of mainly Western patients with docetaxel-na(i)ve and docetaxel-resistant castration-resistant metastatic prostate cancer are valid for Chinese patients,1 The study showed findings with abiraterone for Chinese patients like those previously published.However,it remains an open question whether Chinese patients with prostate cancer differ from Western patients.